Phase 1 trial suggests benefit of psilocybin in OCD treatment
The Brown University Psychopharmacology Update · 2026-08 · 37 (8) · 3-4
DOI: 10.1002/pu.31474 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Brown University Psychopharmacology Update, online erschienen am 28.06.2026.
Abstract (Originalsprache)
A Phase 1 trial comprising 15 patients has found that repeated high‐dose administration of psilocybin was more effective than low‐dose psilocybin or placebo in reducing symptoms of obsessive‐compulsive disorder (OCD). Psilocybin was generally well‐tolerated, with no reports of serious adverse events.
Zitieren
APA
(2026). Phase 1 trial suggests benefit of psilocybin in OCD treatment. The Brown University Psychopharmacology Update, 37(8), 3-4. https://doi.org/10.1002/pu.31474
Vancouver
Phase 1 trial suggests benefit of psilocybin in OCD treatment. The Brown University Psychopharmacology Update. 2026;37(8):3-4. doi:10.1002/pu.31474
BibTeX
@article{euvimed2026,
title = {Phase 1 trial suggests benefit of psilocybin in OCD treatment},
journal = {The Brown University Psychopharmacology Update},
year = {2026},
volume = {37},
number = {8},
pages = {3--4},
doi = {10.1002/pu.31474}
}
EUVIMED